The task order, which is valued at approximately $628 million, came under an existing contract with HHS. It seeks to deploy Emergent’s contract development and manufacturing offering for production of COVID-19 vaccine candidates through 2021, creating a U.S.-based supply chain.
The production will take place at Emergent’s Baltimore Bayview Center for Innovation in Advanced Development and Manufacturing, a facility established in 2012 via a partnership with HHS. The facility, which is designated for rapid manufacturing of treatments and vaccines during public health emergencies, can manufacture hundreds of millions of doses of vaccine yearly.
The task order will also extend viral and non-viral drug product production capabilities at Emergent’s Rockville and Baltimore Camden facilities.
More articles on pharmacy:
Sanofi shakes up leadership, brings in 4 new execs
FDA finds carcinogen in popular diabetes drug
Georgia pharma company recalls thyroid drug for super potency
Sanofi shakes up leadership, brings in 4 new execs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
